Journal of Chemical Health Risks

www.jchr.org

JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

Self-Destructible Antibiotics: Programmable Drug Degradation as a Design Strategy to Mitigate Antimicrobial Resistance

N. *Muthukumar[1] ,Vaiyana Rajesh[2], Dr.Anbazhagan

(Received: 16 February 2026 Revised: 25 March 2026 Accepted: 10 April 2026)

KEYWORDS
self-destructible antibiotics; antimicrobial resistance; programmable degradation; sustainable drug design; nanomedicine; synthetic biology; green chemistry

ABSTRACT:
Antimicrobial resistance (AMR) continues to expand despite sustained efforts in antibiotic discovery, stewardship, and infection control. A key yet under addressed contributor to resistance evolution is the prolonged biological activity of antibiotics beyond their therapeutic window, particularly following excretion into environmental systems. Persistent low-level exposure imposes continuous selective pressure on microbial communities, accelerating resistance emergence and dissemination across clinical and ecological boundaries. Self-destructible antibiotics (SDAs) have emerged as a novel design paradigm that seeks to align antimicrobial efficacy with controlled post-therapeutic deactivation. Rather than maximizing chemical stability alone, SDAs incorporate built-in mechanisms that enable predictable inactivation after clinical utility is achieved. This review synthesizes advances in chemical self-immolative systems, nano pharmaceutical delivery platforms, enzyme- and microbiome-responsive degradation strategies, and synthetic biology–based control mechanisms that collectively enable programmable antibiotic lifespans. By integrating concepts from green chemistry, evolutionary biology, and precision medicine, SDAs represent a shift from use-dependent stewardship to design-enforced responsibility. We critically evaluate the conceptual foundations, technological approaches, translational barriers, and sustainability implications of SDAs, positioning them as a forward-looking strategy to reduce resistance selection while preserving therapeutic effectiveness.



Introduction

1. Antimicrobial Resistance as a Design Challenge

Antimicrobial resistance is widely recognized as one of the most serious threats to modern medicine, compromising routine infection management and high-risk interventions such as surgery, chemotherapy, and transplantation. The inappropriate antibiotic use remains a major driver, resistance persists even under optimized prescribing practices and this persistence reflects a deeper structural issue that most antibiotics are designed to remain biologically active far longer than clinically necessary.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727



Figure 1 Antimicrobial resistance (AMR) highlights its major contributing factors, including inappropriate and excessive antibiotic use, over-prescribing of broad-spectrum drugs, poor sanitation, poor-quality antibiotics, agricultural misuse, global travel, inadequate infection control, and limited diagnostic facilities

Following administration, many antibiotics are incompletely metabolized and are released into wastewater, soils, and aquatic environments in active forms. These residues expose environmental microbiota to sustained sub-therapeutic concentrations, creating ideal conditions for resistance evolution and horizontal gene transfer. As resistance genes circulate freely between environmental and pathogenic bacteria, clinical stewardship alone becomes insufficient.

This realization has prompted growing interest in reframing antibiotics not only as therapeutic agents but also as ecological actors. From this perspective, resistance is not simply a failure of compliance or discovery, but a consequence of how antibiotics are chemically and biologically designed.

2. Limitations of Existing AMR Mitigation Strategies



Figure 2 Approaches like stewardship, combination therapy, phage/CRISPR, and environmental remediation, antibiotics still have an uncontrolled lifespan after treatment. This leads to continuous selective pressure on bacteria, which ultimately causes faster development of antibiotic resistance.

Traditional strategies to mitigate antimicrobial resistance (AMR) have largely focused on downstream control of resistance rather than upstream control of antibiotic lifespan, which represents a fundamental conceptual limitation. Although the discovery of new antibiotics has historically driven infectious disease management, this pipeline has markedly slowed due to high development costs, scientific complexity, and diminishing commercial incentives. Moreover, many newly introduced agents are often close structural analogues of existing drugs, making them vulnerable to **rapid cross-resistance** through already prevalent resistance mechanisms such as efflux pumps, target modification, and enzymatic degradation.

Antimicrobial stewardship programs and optimized dosing regimens have demonstrated value in reducing inappropriate use and improving clinical outcomes; however, their impact is largely confined to the point of prescription and administration. These approaches cannot regulate antibiotic fate after excretion, where significant fractions of active drugs enter wastewater, soil, and agricultural ecosystems. As a result, environmental microbiota are chronically exposed to sub-inhibitory concentrations, sustaining selective pressure and facilitating horizontal gene transfer of resistance determinants.

Combination therapies and antibiotic adjuvants, including β-lactamase inhibitors or efflux pump blockers, enhance antimicrobial potency and delay resistance emergence at the patient level. Paradoxically, by stabilizing antibiotic activity and prolonging exposure, these strategies may **extend environmental persistence**, thereby shifting rather than eliminating resistance selection. Similarly, alternative modalities such as antimicrobial peptides, bacteriophages, and CRISPR-based antimicrobials offer high specificity and innovative mechanisms of action but face significant barriers related to delivery efficiency, host immune interactions, manufacturing scalability, regulatory uncertainty, and real-world clinical translation. Environmental remediation strategies—such as advanced wastewater treatment, adsorption, or biodegradation—attempt to mitigate antibiotic contamination after release. While important, these interventions are inherently reactive and **address pollution rather than prevention**, requiring continuous infrastructure investment without eliminating the root cause. Collectively, existing AMR mitigation strategies treat resistance as an external consequence of antibiotic

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

use rather than as a **design failure of the drug itself**. Consequently, antibiotic lifespan remains largely unmanaged, allowing selective pressure to persist long after therapeutic benefit has been achieved, thereby perpetuating the global AMR crisis.

3. Conceptual Basis of Self-Destructible Antibiotics

Figure 3 Explains the concept of self-destructible antibiotics, which work normally during treatment but are designed to break down after use. It highlights key features such as controlled and trigger-based degradation, maintained effectiveness, and environmental safety, helping reduce antibiotic resistance by limiting unnecessary exposure.

Self-destructible antibiotics (SDAs) represent a paradigm shift in antimicrobial design, in which the *temporal lifespan* of an antibiotic is treated as a controllable pharmacological parameter rather than an unavoidable consequence of chemical stability. These agents are deliberately engineered to exhibit full and uncompromised therapeutic activity during the intended treatment window, followed by programmed inactivation once their clinical function is complete. Unlike conventional antibiotics that rely on slow, passive environmental degradation, SDAs incorporate built-in self-limiting mechanisms at the molecular or formulation level, ensuring that deactivation occurs in response to predefined biological, chemical, or time-dependent cues such as enzymatic exposure, pH shifts, redox conditions, microbiome activity, or carrier disassembly.

A defining feature of SDAs is programmability, whereby degradation kinetics are rationally designed and predictable, enabling precise control over when and where antimicrobial activity ceases. This is coupled with trigger dependence, ensuring that inactivation occurs only after therapeutic action—thereby preserving clinical efficacy while preventing unintended loss of potency. Importantly, SDAs are engineered to maintain pharmacodynamic and pharmacokinetic equivalence to conventional antibiotics during treatment, avoiding compromises in dosing, spectrum, or bacterial killing. Following inactivation, SDAs yield ecologically neutral degradation products that lack antimicrobial activity and do not exert selective pressure on commensal or environmental microbiota.

By constraining both the duration and spatial distribution of antibiotic exposure, SDAs directly shrink the evolutionary window in which resistant subpopulations can emerge and propagate. This design philosophy reframes AMR as a drug-lifecycle engineering problem, addressing resistance at its source rather than relying solely on stewardship or remediation. As such, SDAs offer a rational, sustainability-oriented approach that aligns therapeutic success with long-term ecological and evolutionary safety.

. 4. Chemical Self-Immolative Systems

Chemical self-immolative systems enable molecular-level precision in programming antibiotic deactivation, making them a foundational strategy within the self-destructible antibiotic (SDA) framework. These systems are designed such that a single, well-defined triggering event initiates a rapid and irreversible cascade fragmentation, leading to complete structural disassembly of the antibiotic or its carrier and, consequently, decisive loss of biological activity. Unlike gradual hydrolysis or nonspecific degradation, self-immolation is binary and deterministic, ensuring that antimicrobial function is maintained up to the point of activation and eliminated immediately thereafter.

Common self-immolative architectures include para-aminobenzyl (PAB)–based linkers, which undergo 1,6-elimination after trigger cleavage; quinone methide–forming systems, where transient electrophilic intermediates drive spontaneous fragmentation; and cyclization-driven motifs, in which intramolecular ring formation releases the active drug and simultaneously destroys the linker scaffold. These motifs can be selectively activated by pathogen-associated enzymes (such as β-lactamases or esterases), local pH gradients characteristic of infection sites, or redox conditions linked to inflammatory microenvironments. When incorporated into prodrug constructs or polymer-antibiotic conjugates, self-immolative linkers allow antibiotics to perform their therapeutic function and then

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

deactivate rapidly after target engagement or environmental transition.

The principal advantage of self-immolative systems lies in their speed, specificity, and programmability, enabling tight temporal control over antibiotic lifespan without compromising initial potency. However, successful translation requires careful balancing of chemical stability during manufacturing, storage, and systemic circulation with sufficient sensitivity to the intended trigger. Premature activation could reduce efficacy, whereas excessive stability could undermine the self-destruction objective. Additionally, comprehensive toxicological and environmental evaluation of fragmentation by-products is critical to ensure that degradation products are inert, non-selective, and safe. Despite these challenges, chemical self-immolative systems offer a powerful and elegant approach to embedding resistance-aware design directly into antibiotic molecular architecture.

5. Nanopharmaceutical Control of Antibiotic Lifespan



Figure 4 Nanotechnology is used to control the lifespan of antibiotics. Antibiotics are carried in nanoparticles or lipid-based systems that release the drug at infection sites and then break down. This reduces unnecessary exposure, limits antibiotic resistance, and improves treatment accuracy.

Nanotechnology provides a **systems-level framework for regulating antibiotic exposure**, enabling simultaneous control over drug delivery, spatial localization, and post-therapeutic degradation—capabilities that are not achievable with free antibiotics alone. By encapsulating or conjugating antibiotics within engineered nanocarriers, nanopharmaceutical self-destructible antibiotics (SDAs) can be designed to **confine antimicrobial activity to the site of infection**, protect the drug during circulation, and actively terminate activity once therapeutic goals are met. This integrated control transforms antibiotic use from a passive diffusion process into a **programmable, spatiotemporally regulated intervention**.

Key nanoplatforms include **biodegradable polymeric nanoparticles** such as poly(lactic-co-glycolic acid) (PLGA) and chitosan, which offer tunable degradation rates, high drug-loading capacity, and established biocompatibility. **Lipid-based carriers**, including liposomes and lipid–polymer hybrids, provide membrane-mimetic properties that enhance cellular uptake and intracellular delivery, particularly against intracellular pathogens. **Hybrid organic–inorganic systems**, such as polymer–silica or metal–organic frameworks, enable precise structural control and multifunctionality, including imaging or responsive degradation. Importantly, these platforms can be engineered to respond to **infection-associated stimuli**—such as acidic pH, bacterial enzymes, reactive oxygen species, or inflammatory signals—triggering targeted drug release followed by **rapid carrier disassembly and antibiotic inactivation**.

From an evolutionary perspective, Nano pharmaceutical SDAs directly address a key driver of antimicrobial resistance: **prolonged exposure to sub-inhibitory antibiotic concentrations**. By ensuring that antimicrobial activity is intense, localized, and short-lived, these systems reduce selective pressure on commensal microbiota and environmental bacteria, thereby limiting resistance amplification and horizontal gene transfer. At the same time, targeted delivery improves therapeutic precision, potentially lowering required doses and minimizing off-target toxicity. Collectively, nanotechnology-enabled SDAs align clinical efficacy with ecological responsibility, positioning nanopharmaceutical design as a critical tool in sustainable AMR mitigation.

6. Enzyme- and Microbiome-Responsive Degradation

Biological triggers endow self-destructible antibiotic (SDA) systems with **contextual intelligence**, allowing antimicrobial activity to be regulated by the biological environment rather than by time alone. By coupling antibiotic stability or inactivation to specific enzymatic signals, SDAs can dynamically respond to the presence, identity, and physiological state of microorganisms. This approach ensures that antibiotic action is **conditional**

Journal of Chemical Health Risks

www.jchr.org

JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

and adaptive, intensifying in pathogenic settings while diminishing rapidly once selective pressure is no longer therapeutically justified.

A particularly powerful strategy involves exploiting **resistance- and virulence-associated enzymes** as triggers for SDA deactivation. Enzymes such as β-lactamases—traditionally viewed as drivers of resistance—can be repurposed to initiate antibiotic degradation or carrier self-immolation, effectively **turning resistance mechanisms against the pathogen itself**. In this design, bacteria expressing higher levels of resistance enzymes accelerate the inactivation of the antibiotic, limiting prolonged exposure and reducing the evolutionary advantage of resistance. Similarly, **virulence-linked enzymes** (e.g., proteases, phospholipases) can be used to scale antimicrobial activity with pathogenic threat, enabling strong action at sites of active infection while minimizing exposure in benign or colonized tissues.

In parallel, **microbiome-aware SDA design** seeks to preserve commensal microbial communities by aligning antibiotic deactivation with enzymes predominantly produced by non-pathogenic microbiota. Once antibiotics diffuse beyond the infection site into commensal-rich environments, microbiome-derived enzymatic activity can trigger rapid inactivation, thereby **preventing unnecessary collateral damage and reducing dysbiosis**. This selective degradation not only protects microbial diversity but also limits the emergence and dissemination of resistance genes within the gut and environmental reservoirs. Collectively, biologically triggered SDAs represent a sophisticated integration of microbiology, enzymology, and drug design, transforming antibiotics from indiscriminate agents into **environment-responsive therapeutics** aligned with both clinical efficacy and ecological balance.

7. Synthetic Biology and Genetic Control

Synthetic biology significantly expands the functional scope of self-destructible antibiotics (SDAs) by introducing adaptive, feedback-regulated control mechanisms that go beyond static chemical or material-based triggers. By integrating genetic logic into antimicrobial systems, antibiotic activity can be dynamically modulated in response to time, microbial signals, or resistance emergence, transforming SDAs into responsive therapeutic platforms rather than fixed-dose agents.

One key approach involves genetic timers and regulatory circuits, such as oscillators, delay elements, or inducible kill-switches, which precisely define the duration of antibiotic availability. These systems can be programmed to terminate antibiotic production or activity after a predetermined therapeutic window, ensuring effective bacterial killing while preventing prolonged exposure that favors resistance fixation. Importantly, such circuits can incorporate feedback from bacterial load or inflammatory signals, enabling context-dependent adjustment of antibiotic intensity and duration.

Synthetic biology also enables the development of living therapeutics, in which engineered probiotic or commensal microbes locally synthesize antibiotics at the site of infection. These organisms can be designed with built-in self-limiting genetic controls that halt antibiotic production once pathogen burden decreases or after a fixed number of replication cycles. This localized, transient production minimizes systemic drug exposure, reduces off-target toxicity, and substantially limits environmental release of active antibiotics.

Additionally, CRISPR-enabled regulation introduces unprecedented specificity into SDA systems. CRISPR-based sensors can be engineered to detect defined resistance genes or mobile genetic elements within bacterial populations. Upon recognition of these sequences, the system can trigger antibiotic inactivation, halt further drug release, or initiate self-immolative pathways, thereby preventing selective amplification of resistant subpopulations. Collectively, synthetic biology-driven SDAs embody a convergence of genetic engineering, control theory, and antimicrobial pharmacology, offering a forward-looking strategy in which antibiotic action is not only potent but also self-regulating, resistance-aware, and evolutionarily informed.

8. Environmental Fate and Sustainability

Antibiotics are increasingly recognized as environmentally active contaminants, as even trace concentrations can exert selective pressure on microbial communities and promote the dissemination of resistance genes across ecosystems. Conventional pharmaceutical design prioritizes chemical stability to ensure shelf life and therapeutic reliability, inadvertently enabling antibiotics to persist long after clinical use. Self-destructible antibiotics (SDAs) address this challenge at its source by embedding controlled degradability directly

Journal of Chemical Health Risks
www.jchr.org
JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

into drug design, thereby shifting AMR mitigation from reactive environmental cleanup to proactive pollution prevention.

From a green chemistry perspective, SDAs align closely with key sustainability principles, particularly *design for degradation*, whereby pharmaceuticals are engineered to break down into inactive, non-toxic products after fulfilling their therapeutic function. By preventing the release of long-lived bioactive residues, SDAs inherently support pollution prevention rather than post-release remediation. Furthermore, the intentional generation of ecologically benign degradation products reduces unintended toxicity to non-target organisms, safeguarding microbial diversity in soil, water, and wastewater ecosystems.

To systematically assess the sustainability benefits of SDAs, novel lifecycle-based evaluation metrics are required to complement traditional pharmacokinetic and efficacy endpoints. Proposed frameworks may include an *active lifetime index*, quantifying the duration of biologically active exposure; an *environmental persistence factor*, capturing stability across environmental compartments; and a *selective pressure footprint*, estimating the cumulative resistance-driving impact on microbial populations. Additionally, a *resistance risk index* can integrate biological activity, exposure duration, and ecological distribution to provide a predictive measure of AMR potential. Together, these metrics enable a holistic assessment of antibiotic performance across its entire lifecycle, supporting regulatory decision-making and reinforcing SDAs as a sustainable, evolution-conscious approach to antimicrobial therapy.

9. Translational and Regulatory Considerations

Despite their strong conceptual and translational promise, self-destructible antibiotics (SDAs) face significant practical and regulatory challenges that must be addressed before widespread clinical adoption is feasible. One of the primary hurdles lies in manufacturing complexity and scalability, as SDA designs often incorporate advanced chemistries, responsive linkers, nanocarriers, or biological components that are more intricate than conventional small-molecule antibiotics. Achieving consistent large-scale production while maintaining batch-to-batch reproducibility, cost efficiency, and regulatory compliance represents a substantial technical barrier.

A central formulation challenge is the need to balance long-term storage stability with rapid, trigger-induced degradation during use. SDAs must remain chemically and functionally stable throughout manufacturing, transport, and shelf life, yet respond reliably and predictably to specific biological or environmental cues once administered. This dual requirement necessitates rigorous stability testing and precise control over material properties. In parallel, comprehensive safety and toxicological evaluation of degradation products is essential, as regulatory authorities will require assurance that both primary compounds and their breakdown products are non-toxic, non-immunogenic, and environmentally inert.

From a regulatory standpoint, SDAs challenge existing frameworks that evaluate antibiotics primarily on efficacy, safety, and resistance development at the patient level. The concept of lifecycle-managed drugs, whose activity is intentionally time-limited and environmentally responsive, may require new classification pathways and guidance documents. Furthermore, clinical trial designs must evolve to incorporate SDA-specific endpoints, such as duration of biological activity, environmental clearance profiles, and impact on commensal microbiota and resistance markers. Early and continuous engagement with regulatory agencies, coupled with the adoption of quality-by-design (QbD) principles, will be critical to align scientific innovation with regulatory expectations and to ensure that SDAs can progress efficiently from laboratory concepts to clinically and environmentally responsible therapeutics.

10. Future Directions and Conclusions

Self-destructible antibiotics (SDAs) embody a fundamental reorientation of antimicrobial design philosophy, shifting the goal from maximizing chemical persistence to achieving controlled, sufficient therapeutic exposure. This transition directly confronts antimicrobial resistance at its evolutionary origin by limiting the duration and spatial extent of selective pressure. Rather than attempting to outpace resistance through continual discovery of new drugs, SDAs seek to reshape the selective landscape itself, reducing the probability that resistance traits will emerge, stabilize, and disseminate across microbial populations.

Future progress in this field will rely on advances in trigger specificity, enabling SDAs to respond exclusively to well-defined biological or environmental cues

Journal of Chemical Health Risks

www.jchr.org

JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

associated with infection, resistance, or pathogenic activity. Enhanced specificity will minimize premature inactivation while ensuring rapid deactivation once therapeutic objectives are met. In parallel, the development of multi-layered control architectures—combining chemical, nanotechnological, and biological triggers—will provide redundancy and robustness, ensuring reliable performance across diverse physiological and ecological contexts. Such hierarchical designs can integrate time-based decay, enzyme responsiveness, and environmental sensing to achieve finely tuned antibiotic lifecycles.

Equally critical will be the application of predictive modeling of resistance dynamics, incorporating evolutionary biology, pharmacokinetics, microbiome interactions, and environmental fate. These models can guide rational SDA design by forecasting how different degradation profiles influence resistance trajectories over time. Integration with digital health platforms and AI-driven drug design will further accelerate optimization, enabling data-driven selection of triggers, materials, and molecular architectures while supporting real-time monitoring of treatment outcomes and resistance signals.

If sustained selective pressure is the primary driver of antimicrobial resistance, then embedding a defined and enforceable endpoint into antibiotic activity represents a powerful and rational countermeasure. In this context, SDAs offer more than a technological innovation; they provide a conceptual framework for evolution-aware therapeutics. By aligning clinical efficacy with ecological stewardship, SDAs chart a path toward antimicrobial agents that remain effective over the long term while responsibly coexisting with microbial ecosystems and the environment.

References:

1. Murray CJL et al. (2022). Global burden of bacterial antimicrobial resistance in 2019. *The Lancet*, 399, 629–655.
2. Emergence of environmental antibiotic resistance: Mechanism, monitoring and management Shishir Bobate a,b,1 , Sejal Mahalle a,1 , Nishant A. Dafale a,b , Abhay Bajaj a,b,2,
3. Environmental dimensions of antibiotic resistance: assessment of basic science gaps Kornelia Smalla1, Kimberly Cook2, Steven P. Djordjevic3, Uli Klumper ¨ 4 and Michael Gillings5
4. Recent advances in self-immolative linkers and their applications in polymeric reporting systems Alexander G. Gavriel, Mark R. Sambrook, Andrew T. Russell and Wayne Hayes
5. Targeted Drug Delivery Strategies in Overcoming Antimicrobial Resistance: Advances and Future Directions OhoudM.Alidriss 1,*, Hamood AlSudais 1 , Ohoud S. Alhumaidan 1, Haifa D. Altwaijry 1, Afnan Bakhsh 1 Yasir Almuhanna 2 , Zeina S. Alkudmani 1 , Ibrahim A. Alqarni 3 , , Daheeya Alenazi 1, Alanoud T. Aljasham 1 and Yahya F. Jamous 4,
6. Antimicrobial Resistance: Techniques to Fight AMR in Bacteria – A Review Ernessto Mahizhchi, Diveyaa Sivakumar and Megala Jayaraman
7. Combating antibiotic resistance: mechanisms, challenges, and innovative approaches in antibacterial drug development Aiswarya M. Rajesh1 , Shraddha Subhash Pawar1 , Kruthi Doriya2* , Rambabu Dandela1*
8. Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance in vitro Mari Yoshida1, Sabrina Galin˜anes Reyes1, Soichiro Tsuda1, Takaaki Horinouchi2, Chikara Furusawa2,3 & Leroy Cronin1
9. Larsson DGJ, Flach CF. Antibiotic resistance in the environment. *Nat Rev Microbiol.* 2022;20:257–269.
10. Bengtsson-Palme J et al. Environmental factors influencing the development and spread of antibiotic resistance. *FEMS Microbiol Rev.* 2018;42: fux 053.
11. Wellington EMH et al. The role of the natural environment in the emergence of antibiotic resistance. *Lancet Infect Dis.* 2013;13:155–165.
12. Singer AC et al. Review of antimicrobial resistance in the environment. *Environ Int.* 2016;93:347–35
13. Kraemer SA et al. Role of the environment in the spread of antimicrobial resistance. *Nat Rev Microbiol.* 2019;17:744–758.
14. Wright GD. Antibiotics: A new hope. *Chem Biol.* 2012;19:3–10.
15. Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. *Nature.* 2016;529:336–343.
16. McEwen SA, Collignon PJ. Antimicrobial resistance: A One Health perspective. *Microbiol Spectr.* 2018;6.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2026) 16(2), 3757-3764 | ISSN:2251-6727

17. Kümmerer K. Antibiotics in the aquatic environment – A review. *Chemosphere.* 2009;75:417–434.
18. Kümmerer K. Sustainable chemistry in pharmaceutical development. *Green Chem.* 2019;21:119–138.
19. Alouane A et al. Self-immolative spacers: Kinetic and mechanistic insights. *Angew Chem Int Ed.* 2015;54:7492–7509.
20. De Gracia Lux C et al. Biologically triggered self-immolative drug delivery systems. *ACS Cent Sci.* 2018;4:165–179.
21. Roth ME et al. Stimuli-responsive self-immolative polymers. *Chem Rev.* 2021;121:2041–2145.
22. Shabat D. Self-immolative linkers as drug delivery tools. *Chem Commun.* 2022;58:8277–8291.
23. Gnaim S, Shabat D. Activity-based probes and self-immolative systems. *Acc Chem Res.* 2019;52:2806–2817.
24. Blanco E et al. Principles of nanoparticle design for drug delivery. *Nat Biotechnol.* 2015;33:941–951.
25. Mitchell MJ et al. Engineering precision nanoparticles for drug delivery. *Nat Rev Drug Discov.* 2021;20:101–124.
26. Cheng R et al. Environment-responsive nanomedicine. *Chem Rev.* 2022;122:5313–5367.
27. Patra JK et al. Nano based drug delivery systems: Recent developments. *J Nanobiotechnol.* 2018;16:71.
28. Khan I et al. Biodegradable polymeric nanoparticles in antimicrobial delivery. *Pharmaceutics.* 2023;15:1129.
29. Rautio J et al. Prodrugs: Design and clinical applications. *Nat Rev Drug Discov.* 2018;17:559–587.
30. Yang NJ, Hinner MJ. Getting across the cell membrane: An overview. *Methods Mol Biol.* 2015;1266:29–53.
31. Böttcher T, Sieber SA. β-Lactam antibiotics: Mechanistic insights. *J Am Chem Soc.* 2008;130:14400–14401.
32. Sletten EM, Bertozzi CR. Bioorthogonal chemistry. *Angew Chem Int Ed.* 2009;48:6974–6998.
33. LiJ etal. Enzyme-responsive nanomedicines. *Adv Sci.* 2020;7:1902939.
34. Weber W, Fussenegger M. Emerging biomedical applications of synthetic biology. *Nat Rev Genet.* 2012;13:21–35.
35. Cameron DE et al. A brief history of synthetic biology. *Nat Rev Microbiol.* 2014;12:381–390.
36. de Lorenzo V et al. Biotechnology of antibiotic degradation. *Microb Biotechnol.* 2018;11:819–823.
37. Mimee M et al. Microbiome engineering. *Cell.* 2016;165:555–566.
38. Riglar DT, Silver PA. Engineering bacteria for diagnostic and therapeutic applications. *Nat Rev Microbiol.* 2018;16:214–225.
39. Anastas PT, Warner JC. Green Chemistry: Theory and Practice. Oxford Univ Press, 1998.
40. Sheldon RA. Green chemistry and resource efficiency. *Green Chem.* 2017;19:18–43.
41. Daughton CG. Pharmaceuticals in the environment: Stewardship. *Environ Health Perspect.* 2003;111:757–774.
42. Aus der Beek T et al. Pharmaceuticals in the environment—Global occurrences. *Environ Toxicol Chem.* 2016;35:823–835.
43. Michael I et al. Urban wastewater treatment and antibiotic resistance. *Water Res.* 2013;47:957–995.
44. Ventola CL. The antibiotic resistance crisis. *P&T.* 2015;40:277–283.
45. Laxminarayan R et al. Access, conservation, and innovation in antibiotics. *Lancet.* 2016;387:168–175.
46. WHO. Global action plan on antimicrobial resistance. World Health Organization,
47. O'Neill J. Tackling drug-resistant infections globally. Review on AMR, UK Govt.,
48. Tacconelli E et al. WHO priority pathogens list. *Lancet Infect Dis.* 2018;18:318–327.
49. Lewis K. The science of antibiotic discovery. *Cell.* 2020;181:29–45.
50. Hutchings MI et al. Antibiotics: Past, present and future. *Curr Opin Microbiol.* 2019;51:72–80.
51. Kang Y et al. Smart antimicrobial nanomaterials. *Adv Drug Deliv Rev.* 2022;188:114447.
52. Xiong MH et al. Degradable nanocarriers for precision medicine. *Adv Funct Mater.* 2020;30:1909000.
53. Zhao Y et al. Environment-responsive antibiotic delivery systems. *Front Bioeng Biotechnol.* 2023;11:1184457.